Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

176
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
176
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

209
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
209
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

227
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
227
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.3K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

157
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
157

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-implementation safety evaluation of an AI decision-support system for surgical antimicrobial prophylaxis.

Internal medicine journal·2026
Same author

Worldwide Impact of Human Development and Inequality on the Prevalence of Asthma, Rhinoconjunctivitis and Eczema. Global Asthma Network's Ecological Study.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

NETosis associates with human TB lung tissue destruction and disease pathogenesis.

EMBO molecular medicine·2026
Same author

Is Digitoxin the Fifth Pillar in Heart Failure With Reduced Ejection Fraction? A Response to the DIGIT-HF Trial.

Heart, lung & circulation·2026
Same author

Artificial Intelligence Deep Learning Methods in the Assessment of Cardiovascular Risk for Patients With Autoimmune Diseases: A Promising Prospect.

Heart, lung & circulation·2026
Same author

'Real time, real change': the role of artificial intelligence in providing real-time language translation services in regional medicine.

Internal medicine journal·2026

Related Experiment Video

Updated: Jun 18, 2025

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

11.8K

Bedaquiline: what might the future hold?

Emily S Shaw1, Neil G Stoker2, Jessica L Potter3

  • 1Division of Acute Medical Services, University College London Hospitals NHS Foundation Trust, London, UK.

The Lancet. Microbe
|July 29, 2024
PubMed
Summary

Bedaquiline offers a breakthrough for drug-resistant tuberculosis treatment. Ensuring global access and preventing resistance are crucial for this vital tuberculosis drug.

More Related Videos

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

832
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

Related Experiment Videos

Last Updated: Jun 18, 2025

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

11.8K
Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models
04:59

Author Spotlight: Developing a Disposable Dosator for Preclinical Testing of Dry Powder Inhalers in Small Animal Models

Published on: August 18, 2023

832
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Global Health

Background:

  • Tuberculosis drug development has seen limited progress for decades.
  • Bedaquiline represents a significant advancement, now recommended as first-line therapy for drug-resistant tuberculosis by the WHO.
  • Current treatment regimens offer safer and more effective oral options.

Purpose of the Study:

  • To evaluate the current evidence on bedaquiline-containing regimens.
  • To identify obstacles to global access and strategies to prevent drug resistance.
  • To discuss the potential expansion of bedaquiline use and lessons for future drug development.

Main Methods:

  • Review of current evidence.
  • Analysis of challenges based on an international workshop (2023).
  • Discussion of access issues and resistance concerns.

Main Results:

  • Bedaquiline-containing regimens have transformed drug-resistant tuberculosis treatment.
  • Key challenges include ensuring global access and mitigating the rise of resistance.
  • Potential exists for broadening bedaquiline use beyond current indications.

Conclusions:

  • Bedaquiline is a critical tool, but its long-term efficacy depends on addressing access and resistance.
  • Strategic planning is needed to balance increased utilization with resistance prevention.
  • Lessons learned from bedaquiline inform the development and deployment of future tuberculosis drugs.